Article
The promise and peril of KRAS G12C inhibitors.
Cancer cell - 9 Aug 2021
Moore Amanda R, Malek Shiva
Abstract excerpt
RAS mutant tumors have been largely refractory to therapies until now. Recent findings published in the New England Journal of Medicine show that sotorasib provides clinical benefit for KRAS p.G12C-mutated non-small-cell lung cancer (NSCLC) and provide mechanistic insights into acquired resistance to KRASG12C-specific inhibition.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.